ProCE Banner Activity

Breaking Down Biologic Therapies in Moderate to Severe Atopic Dermatitis: Who, What, When, Why, and How?

Slideset

The medical need, clinical rationale, and available clinical evidence on biologic therapies for patients with moderate to severe atopic dermatitis are presented. Recommended disease assessment measures that can be integrated into advanced treatment approaches are also highlighted.

Released: October 24, 2024

Expiration: October 23, 2025

Share

Faculty

Sandri Johnson

Sandri Johnson, MSN, FNP-BC, DCNP

Dermatology Nurse Practitioner
Midtown Dermatology
Raleigh and Rocky Mount, North Carolina

Jonathan Silverberg

Jonathan Silverberg, MD, PhD, MPH

Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with the Dermatology Education Foundation Dermalorian™ Webinar Series.

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Partners

Dermatology Education Foundation Dermalorian™ Webinar Series

ProCE Banner